The defining metric for validating within-run precision of an IVD immunoassay is a precision profile benchmark: maintaining a coefficient of variation (%CV) ≤5% across at least 90% of the analytical measuring range.
This standard means that when you repeatedly test the same sample multiple times in a single run, the relative standard deviation of those measurements must stay at or below 5% for nearly the entire range of analyte concentrations the assay claims to detect. Slightly higher %CV is only tolerated at the very lowest and highest ends of the calibration curve. Automated immunoassay platforms routinely meet this mark, while manual methods or ultra‑sensitive assays targeting trace analytes may require additional optimization to reach it.
Core Takeaway
A within-run precision profile must demonstrate ≤5% CV over at least 90% of the measuring range—from the lowest non‑zero calibrator to the highest calibrator. This threshold ensures consistent, reliable results for a diagnostic immunoassay under a single set of operating conditions, and it serves as the primary gatekeeper for assay robustness before moving to inter‑run and lot‑to‑lot studies.
Understanding the Precision Profile and Within‑Run Precision
Before diving deeper into the standard itself, it’s crucial to see how the precision profile acts as both a design tool and a gatekeeper for IVD assay performance.
What Is a Precision Profile?
A precision profile is a graphical and statistical model of your assay’s error across its entire measurement range.
You plot %CV on the y‑axis against analyte concentration on the x‑axis for multiple samples, each measured in duplicate or replicate.
The resulting curve—often U‑shaped—reveals exactly where your assay becomes too imprecise to trust.
Defining Within‑Run Precision and Its Clinical Importance
Within‑run precision (also called intrabatch or intra‑assay precision) is the consistency of results when the same sample is tested multiple times in a single analytical run, using the same reagent lot, the same instrument, and the same operator.
Poor within‑run precision means a patient’s result might fall outside the true value simply due to random error in the assay itself, potentially leading to misdiagnosis or incorrect therapeutic decisions.
That’s why stringent precision standards are non‑negotiable in diagnostic immunoassays.
The Recommended Performance Benchmark: ≤5% CV Over 90% of the Measuring Range
The precision profile standard you’re asking about directly sets the upper limit of acceptable variability for a validated IVD immunoassay.
Breaking Down the Standard
The rule is clear: %CV must be ≤5% for at least 90% of the assay’s analytical measuring range.
The measuring range is defined by your calibration curve—from the lowest non‑zero calibrator to the highest calibrator.
At the extreme upper and lower calibration limits, where signal‑to‑noise ratios naturally degrade, a modest relaxation of the 5% limit is acceptable, but the bulk of the clinical decision range must stay under that tight boundary.
Why This Threshold Matters for Automated Immunoassays
Modern automated immunoassay systems routinely deliver within‑run %CVs of 2‑3% across broad concentration ranges.
Adopting the ≤5% benchmark for validation confirms that your reagents, instrument parameters, and incubation steps are optimized to a level that meets the high expectations of diagnostic laboratories.
If an automated assay can’t hit this number, the root cause (e.g., imprecise liquid handling, unstable conjugates, suboptimal incubation) requires immediate investigation.
Nuances and Broader Acceptance Criteria in IVD Development
While ≤5% CV is the aspirational target for a fully validated diagnostic immunoassay, developmental phases and certain assay formats use different, often wider, acceptance limits.
Early‑Stage Validation vs. Final Product Validation
During pre‑validation of ligand‑binding assays (LBAs), for example, intrabatch precision criteria are often relaxed to %CV ≤20% (and ≤25% at the lower limit of quantification).
These numbers come from the supplementary references and reflect the reality that early assay prototyping prioritizes feasibility and dynamic range over ultra‑tight precision.
However, when an IVD immunoassay is being finalized for market release and clinical use, the standard tightens to the ≤5% CV threshold described in the primary reference.
Impact of Assay Format and Matrix Effects
Manual assays, ultra‑sensitive methods, or assays targeting very low analyte concentrations in complex biological matrices (e.g., serum, plasma) may struggle to maintain ≤5% CV across 90% of the range.
In such cases, optimization of antibody‑antigen pairing, conjugate concentrations, and wash steps is required to push %CV as low as possible.
But if the intrinsic biology or sample preparation inherently caps achievable precision, developers may justify a slightly higher %CV (e.g., ≤8–10%) in certain low‑concentration segments, provided that clinical risk is still acceptable and the limitation is clearly documented.
Understanding the Trade‑offs
A purely numbers‑driven pursuit of ≤5% CV isn’t without compromises. You must weigh precision against other performance attributes.
Strict Precision Limits Can Constrict Your Reportable Range
If you force your assay to hit ≤5% CV across the entire calibration range, you might have to truncate the upper and lower ends where imprecision creeps above the threshold.
This reduces the assay’s effective working range, potentially requiring sample dilutions or sacrificing low‑end sensitivity.
5% CV May Not Be Realistic for All Assay Types
For manual or point‑of‑care immunoassays, operator variability and environmental factors inherently introduce more noise.
Aiming for ≤5% CV might be unattainable—or achievable only through costly automation that may not align with the product’s intended use.
In these scenarios, a tiered validation approach (e.g., ≤10% CV for the clinical decision range) can still provide diagnostically valid results, as long as the performance is clearly communicated to users.
Actionable Steps: How to Build and Interpret Your Precision Profile
Translating the standard into a concrete experimental plan is the key to a successful within‑run validation.
Experimental Design for a Within‑Run Precision Profile
Select at least 25 clinical samples (or spiked matrix samples) that span your entire intended measuring range.
Test each sample in a minimum of 2–3 replicates (supplementary references suggest 5–6 replicates for robust intrabatch estimates).
Divide the concentration data into 5–10 bins, then model the response‑error relationship and transform response SD into %CV at each bin using the local slope of your calibration curve.
Setting Your Working Range and Functional Sensitivity
Once your precision profile is plotted, draw a horizontal line at 5% CV. The concentrations where the curve drops below this line define the lower and upper limits of your validated working range.
Any segment beyond these limits should not be reported without a disclaimer.
For low‑concentration samples, the precision profile also helps pin down functional sensitivity—the lowest concentration at which %CV reliably stays ≤5% (or an acceptable clinical limit).
Making the Right Choice for Your Goal
The precision profile standard you adopt depends on your assay’s intended use and development stage. Use these goal‑oriented guides to decide.
- If your primary focus is final validation of a standardized automated IVD immunoassay: Adhere strictly to the ≤5% CV standard over at least 90% of the measuring range; treat any excursions as a signal to optimize reagents or revisit the calibration model.
- If your primary focus is early‑stage assay development or feasibility testing: Apply broader intrabatch criteria (e.g., %CV ≤20%) to quickly screen candidate antibody pairs and buffer conditions, then progressively tighten limits as the assay matures.
- If your primary focus is a manual, ultra‑sensitive, or matrix‑challenged immunoassay: Aim for ≤5% CV but recognize that a slightly relaxed threshold (e.g., ≤10% CV) may be clinically acceptable for the intended use, provided you transparently characterize the working range and the precision‑concentration curve.
A well‑constructed precision profile not only answers the question of whether your within‑run precision is acceptable—it tells you exactly where your assay excels and where it needs refinement, empowering you to bring a robust, trustworthy diagnostic tool to the clinic.
Summary Table:
| Assay Stage / Format | Recommended Precision Benchmark (%CV) | Target Coverage | Key Validation Focus |
|---|---|---|---|
| Final IVD Validation | %CV ≤ 5% | ≥ 90% of measuring range | Standard gatekeeper for market release and clinical use |
| Automated Immunoassays | 2% – 3% CV | Broad measuring range | Validates optimized liquid handling & conjugate stability |
| Early Feasibility / LBA | %CV ≤ 20% (≤25% at LLOQ) | Intrabatch screening | Quick screening of antibody pairs & dynamic range |
| Manual / Ultra-Sensitive | %CV ≤ 8% – 10% | Segmented / Low-end range | Justified when matrix effects cap achievable precision |
Optimize Your Immunoassay Performance with CamelBio
Struggling to hit the ≤5% CV precision profile standard across your assay's measuring range? CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to premium IVD raw materials, assay optimization services, and validation consulting—supporting your product at every stage from concept to clinic.
Whether you need high-affinity antibody-antigen pairs, custom buffer formulations, or expert guidance on analytical validation: